LAUSR

national tender process with higher prices per unit for standard FVIII and FIX concentrates, the absence of difference in price per unit for standard FVIII and EHLFVIII concentrates, the only recent introduction of a network of certified haemophilia treatment centres, and the absence of a national registry (and associated collection of patient data, as performed for decades within the UK health system by the UKHCDO) all influence how EHLs will be integrated into clinical practice in Belgium, and their potential impact on patient management. UKHCDO guidance provides a robust framework to agree an approach to the use of EHL CFCs in routine clinical practice. This framework should be reviewed in the context of each country ’ s unique healthcare system and adapted accordingly.